Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Additional Paid-In Capital : $0.00 Mil(As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals Additional Paid-In Capital?

Cumberland Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Cumberland Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals Additional Paid-In Capital Chart

Cumberland Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

Cumberland Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	-	-	-

Cumberland Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cumberland Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203

Website

https://www.cumberlandpharma.com

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.

Executives

Todd M. Anthony	officer: Vice Pres Organizational Dev	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman	officer: Vice Pres Sales & Marketing	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante	director	111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones	director	2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr	director	850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi	director, 10 percent owner, officer: Chairman and CEO	1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal	director	31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard	officer: Senior Vice President	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs	director	830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence	director	1880 ELLINGTON WAY, AUBURN AL 36830